Additionally, the 36-month beta value for ALVR is 0.76. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALVR is 55.34M and currently, short sellers hold a 11.20% ratio of that float. The average trading volume of ALVR on July 02, 2024 was 421.82K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ALVR) stock’s latest price update
AlloVir Inc (NASDAQ: ALVR)’s stock price has soared by 1.40 in relation to previous closing price of 0.73. Nevertheless, the company has seen a loss of -4.12% in its stock price over the last five trading days. accesswire.com reported 2024-03-19 that NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71800&wire=1 or contact Joseph E. Levi, Esq.
ALVR’s Market Performance
AlloVir Inc (ALVR) has experienced a -4.12% fall in stock performance for the past week, with a -1.95% drop in the past month, and a -3.56% drop in the past quarter. The volatility ratio for the week is 6.84%, and the volatility levels for the past 30 days are at 6.00% for ALVR. The simple moving average for the past 20 days is -2.31% for ALVR’s stock, with a -35.07% simple moving average for the past 200 days.
Analysts’ Opinion of ALVR
Many brokerage firms have already submitted their reports for ALVR stocks, with BofA Securities repeating the rating for ALVR by listing it as a “Underperform.” The predicted price for ALVR in the upcoming period, according to BofA Securities is $1 based on the research report published on December 26, 2023 of the previous year 2023.
ALVR Trading at -3.84% from the 50-Day Moving Average
After a stumble in the market that brought ALVR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.47% of loss for the given period.
Volatility was left at 6.00%, however, over the last 30 days, the volatility rate increased by 6.84%, as shares sank -0.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.36% lower at present.
During the last 5 trading sessions, ALVR fell by -4.15%, which changed the moving average for the period of 200-days by -72.69% in comparison to the 20-day moving average, which settled at $0.7574. In addition, AlloVir Inc saw 8.88% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALVR starting from Brainard Diana, who sale 5,149 shares at the price of $0.79 back on May 21 ’24. After this action, Brainard Diana now owns 784,471 shares of AlloVir Inc, valued at $4,080 using the latest closing price.
Sinha Vikas sale 3,143 shares at $0.75 during a trade that took place back on May 17 ’24, which means that Sinha Vikas is holding 1,129,996 shares at $2,355 based on the most recent closing price.
Stock Fundamentals for ALVR
Current profitability levels for the company are sitting at:
- -19.2 for the present operating margin
- 0.55 for the gross margin
The net margin for AlloVir Inc stands at -21.42. The total capital return value is set at -1.18. Equity return is now at value -114.36, with -92.50 for asset returns.
Based on AlloVir Inc (ALVR), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -7.45. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is -78.58.
Currently, EBITDA for the company is -180.93 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 2.04. The receivables turnover for the company is 46.3for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.48.
Conclusion
In conclusion, AlloVir Inc (ALVR) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
